Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
In his new role, Curtis will lead the formulation and execution of the company’s global technical strategy
Marking three years of the National Diagnostics Catapult (NDxC), the conclave launched the Impact Report and unveiled environmental surveillance kits
Subscribe To Our Newsletter & Stay Updated
